A Phase 4 interventional study of Atazanavir and Atazanavir in HIV, sponsored by Bristol-Myers Squibb. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-08-31.
Sponsored by Bristol-Myers Squibb · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the effects of famotidine, given twice daily, on atazanavir administered with ritonavir and tenofovir in HIV-infected participants.
This protocol was designed to compare the pharmacokinetic parameters of atazanavir administered as atazanavir/ritonavir, 400/100 mg once daily (QD), plus famotidine, 20 mg and 40 mg twice daily, with the parameters found at the usual clinical dose of atazanavir/ritonavir, 300/100 mg QD, without famotidine in HIV-infected participants receiving tenofovir disoproxil fumarate and at least 1 other nucleoside reverse transcriptase inhibitor.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key inclusion criteria:
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
Drug: Atazanavir · Drug: Ritonavir · Drug: Tenofovir (TDF) · Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
Drug: Atazanavir · Drug: Ritonavir · Drug: Tenofovir (TDF) · Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI) · Drug: Famotidine (FAM)
FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
Drug: Atazanavir · Drug: Ritonavir · Drug: Tenofovir (TDF) · Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI) · Drug: Famotidine (FAM)
Capsule, oral, 300 mg, once daily, 10 days
Also known as: Reyataz, BMS-232632
Capsule, oral, 400 mg, once daily, 7 days
Also known as: Reyataz, BMS-232632
Capsule, oral, 100 mg, once daily, 10 days
Capsule, oral, 100 mg, once daily, 7 days
Capsule, oral, 300 mg, once daily, 10 days
Capsule, oral, 300 mg, once daily, 7 days
Oral, 10 days
Oral, 7 days
Tablet, oral, 20 mg, twice daily, 7 days
Tablet, oral, 40 mg, twice daily, 7 days
Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir
Time frame: Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Time of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir
Time frame: Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Area Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir
Time frame: Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: Days 1 through 25 (end of study), continuously, and at study discharge for those who discontinued prematurely.
Number of Participants With Abnormalities in Vital Signs
Vital signs include temperature, respiratory rate, seated blood pressure, and heart rate.
Time frame: Days 1, 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings
ECG findings include heart rate, ECG intervals (including PR, QRS, QT, and corrections to QT using both Bazett's and Fridericia's formulae), and Investigator-identified ECG abnormalities.
Time frame: Days 1 and 25 (end of study) and at study discharge for those who discontinued prematurely.
Number of Participants With Abnormalities in Laboratory Test Results
PreRX=pretreatment; ULN=upper limit of normal. Neutrophils, (absolute), low (10\*3 c/uL): \<0.85\*PreRx, if PreRx \<1.5; \<1.5 if PreRx ≥1.5. Alanine aminotransferase, high (U/L): \>1.25\*PreRx if PreRx \>ULN; \>1.25\*ULN if PreRx ≤ULN. Bilirubin, direct (mg/dL), high: \>1.1\*ULN if PreRx ≤ULN;\> 1.1\*ULN if PreRx is missing; \>1.25\*PreRx if PreRx \>ULN. Bilirubin, total (mg/dL), high: \>1.1\*ULN if PreRx ≤ULN;\> 1.1\*ULN if PreRx is missing; \>1.25\*PreRx if PreRx \>ULN.
Time frame: Days 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.
| Milestone | Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20) | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40) |
|---|---|---|---|
| Started | 25 | 0 | 0 |
| Completed | 24 | 0 | 0 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Discontinued due to dosing error | 1 | 0 | 0 |
| Milestone | Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20) | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40) |
|---|---|---|---|
| Started | 0 | 24 | 0 |
| Completed | 0 | 24 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20) | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40) |
|---|---|---|---|
| Started | 0 | 0 | 24 |
| Completed | 0 | 0 | 24 |
| Not completed | 0 | 0 | 0 |
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| Participants | Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20) | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40) |
|---|---|---|---|
| Deaths | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 |
| AEs leading to discontinuation | 0 | 0 | 0 |
| AEs | 6 | 7 | 5 |
| AEs of clinical interest: Nausea | 0 | 2 | 0 |
| AEs of clinical interest: Diarrhea | 0 | 3 | 0 |
Vital signs include temperature, respiratory rate, seated blood pressure, and heart rate.
| Participants | All Treated |
|---|---|
| Isolated decrease in heart rate | 2 |
| Sporadic respiration rate >16 bpm | 11 |
| ng/mL | Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20) | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40) |
|---|---|---|---|
| Atazanavir Cmax | 3512 ± 35.4 | 4131 ± 37.7 | 3322 ± 45.2 |
| Atazanavir Ctrough | 496 ± 50.9 | 602 ± 60.3 | 494 ± 59.4 |
| Ritonavir Cmax | 1141 ± 30.5 | 1148 ± 29.8 | 1096 ± 36.1 |
| Ritonavir Ctrough | 45.8 ± 58.7 | 49.2 ± 66.8 | 47.3 ± 53.4 |
| Hours | Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20) | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40) |
|---|---|---|---|
| Atazanavir Tmax | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.10) |
| Ritonavir Tmax | 4.0 (2.0 to 4.2) | 4.00 (2.0 to 6.0) | 4.0 (2.0 to 6.0) |
| ng*h/mL | Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20) | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40) |
|---|---|---|---|
| Atazanavir AUC | 32562 ± 37.7 | 37894 ± 40.7 | 31481 ± 48.8 |
| Ritonavir AUC | 7317 ± 35.6 | 7430 ± 32.4 | 7052 ± 36.7 |
ECG findings include heart rate, ECG intervals (including PR, QRS, QT, and corrections to QT using both Bazett's and Fridericia's formulae), and Investigator-identified ECG abnormalities.
| Participants | All Treated |
|---|---|
| Nonspecific ST/T wave abnormality | 1 |
| Short PR interval | 1 |
PreRX=pretreatment; ULN=upper limit of normal. Neutrophils, (absolute), low (10\*3 c/uL): \<0.85\*PreRx, if PreRx \<1.5; \<1.5 if PreRx ≥1.5. Alanine aminotransferase, high (U/L): \>1.25\*PreRx if PreRx \>ULN; \>1.25\*ULN if PreRx ≤ULN. Bilirubin, direct (mg/dL), high: \>1.1\*ULN if PreRx ≤ULN;\> 1.1\*ULN if PreRx is missing; \>1.25\*PreRx if PreRx \>ULN. Bilirubin, total (mg/dL), high: \>1.1\*ULN if PreRx ≤ULN;\> 1.1\*ULN if PreRx is missing; \>1.25\*PreRx if PreRx \>ULN.
| Participants | Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20) | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40) |
|---|---|---|---|
| WBC differential count (low) | 1 | 0 | 0 |
| Neutrophils (absolute) (low) | 0 | 1 | 0 |
| Alanine aminotransferase (high) | 0 | 1 | 0 |
| Aspartate aminotransferase (high) | 0 | 0 | 1 |
| Bilirubin, direct (high) | 1 | 0 | 0 |
| Bilirubin, total (high) | 3 | 7 | 5 |
Collected over Days 1 through 25 (end of study), continuously, and at study discharge for those who discontinued prematurely.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI | — | 0/25 (0%) | 4/25 (16%) |
| Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20) | — | 0/25 (0%) | 6/25 (24%) |
| Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40) | — | 0/24 (0%) | 1/24 (4.2%) |
| Event | Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20) | Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40) |
|---|---|---|---|
| HeadacheNervous system disorders | 4/25 | 1/25 | 1/24 |
| DiarrhoeaGastrointestinal disorders | 0/25 | 3/25 | 0/24 |
| NauseaGastrointestinal disorders | 0/25 | 2/25 | 0/24 |
| Age, Customized(Participants) | All Treated |
|---|---|
| Younger than 65 years | 25 |
| 65 years and older | 0 |
| Sex: Female, Male(Participants) | All Treated |
|---|---|
| Female | 1 |
| Male | 24 |
| Race (NIH/OMB)(Participants) | All Treated |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Age(Years) | All Treated |
|---|---|
| Mean | 39.8 (23 to 62) |
| CD4 Absolute Count(Cells/μL) | All Treated |
|---|---|
| Mean | 584.8 ± 194.09 |
| CD4 Percent of Total(Percent of participants) | All Treated |
|---|---|
| Mean | 32.1 ± 7.10 |
The record gives a start of Feb 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atazanavir · Ritonavir · Tenofovir